Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
- 1 November 1999
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 58 (2) , 157-162
- https://doi.org/10.1023/a:1006391902868
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Randomized Phase III Trial Comparing the New Potent and Selective Third-Generation Aromatase Inhibitor Vorozole With Megestrol Acetate in Postmenopausal Advanced Breast Cancer PatientsJournal of Clinical Oncology, 1999
- Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinomaCancer, 1998
- Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancerAnnals of Oncology, 1998
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancerEuropean Journal Of Cancer, 1997
- Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapyEuropean Journal of Cancer and Clinical Oncology, 1989
- The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breastEuropean Journal of Cancer and Clinical Oncology, 1988
- Assessment of response to therapy in advanced breast cancerPublished by Elsevier ,1977